Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study

• Published in: Clinical and translational science Vol. 16; no. 6; pp. 955 - 965
• Main Authors: Ekman, Simon, Cselényi, Zsolt, Varrone, Andrea, Jucaite, Aurelija, Martin, Heather, Schou, Magnus, Johnström, Peter, Laus, Gianluca, Lewensohn, Rolf, Brown, Andrew P., Aart, Jasper, Vishwanathan, Karthick, Farde, Lars
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.06.2023; John Wiley and Sons Inc; Wiley
• Subjects: Brain; Brain cancer; Brain Neoplasms - diagnostic imaging; Brain Neoplasms - drug therapy; Brain Neoplasms - genetics; Brain tumors; Cancer therapies; Carcinoma, Non-Small-Cell Lung - diagnostic imaging; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Central nervous system; Clinical medicine; Clinical trials; Drug dosages; Epidermal growth factor; Epidermal growth factor receptors; ErbB Receptors - genetics; Humans; Lung cancer; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Magnetic Resonance Imaging; Metastases; Metastasis; Mutation; Nervous system; Neuroimaging; Non-small cell lung carcinoma; Patients; Positron emission tomography; Protein Kinase Inhibitors; Protein-tyrosine kinase; Radioactivity; Small cell lung carcinoma; Solid tumors; Targeted cancer therapy; Tomography; Tumors; Volumetric analysis; Sweden

Brain metastases (BMs) are associated with poor prognosis in epidermal growth factor receptor mutation‐positive (EGFRm) non‐small cell lung cancer (NSCLC). Osimertinib is a third‐generation, irreversible, EGFR‐tyrosine kinase inhibitor that potently and selectively inhibits EGFR‐sensitizing and T790...